SURGERY PARTNERS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.84 USD | -2.59% |
|
+6.06% | -22.35% |
| Mar. 26 | Surgery Partners Unit to Offer $600 Million of Senior Notes | MT |
| Mar. 06 | Surgery Partners Insider Sold Shares Worth $277,633, According to a Recent SEC Filing | MT |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The firm trades with high earnings multiples: 27.45 times its 2024 earnings per share.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -22.35% | 3.13B | C- | ||
| -22.63% | 15.76B | B+ | ||
| +3.60% | 12.34B | B | ||
| +3.65% | 11.52B | B+ | ||
| +10.55% | 11.02B | B+ | ||
| +24.00% | 8.28B | B | ||
| -2.19% | 7.8B | A- | ||
| +20.75% | 7.2B | D | ||
| +4.53% | 6.67B | B- | ||
| +49.97% | 4.64B | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- SGRY Stock
- Ratings Surgery Partners, Inc.
